SCHEMBL1010269

SCHEMBL1010269

COC(=O)C1C(=O)C(C(=O)OC)C2CCC1N2C(=O)OC(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.54
HIF1A Q16665 1/20 0.54
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
ALDH1A1 P00352 2/20 0.39
PREP P48147 3/20 0.37
ABCB1 P08183 1/20 0.36
PDE4B Q07343 1/20 0.36
EPHX1 P07099 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN6 P29350 1/20 0.35
DDB1 Q16531 2/20 0.35
CRBN Q96SW2 2/20 0.35
HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866475 0.91 CYP1A2 (0.49) CYP1A2HIF1ACHRM2CHRM1CHRM3
SCHEMBL15239620 0.84 CHRM2 (0.46) CYP1A2HIF1ACHRM2CHRM1CHRM3
SCHEMBL1012317 0.84 CHRM2 (0.46) CYP1A2HIF1ACHRM2CHRM1CHRM3
SCHEMBL797568 0.84 CHRM2 (0.46) CYP1A2HIF1ACHRM2CHRM1CHRM3
SCHEMBL29642341 0.84 CHRM2 (0.46) CYP1A2HIF1ACHRM2CHRM1CHRM3
SCHEMBL7646464 0.84 CHRM2 (0.46) CYP1A2HIF1ACHRM2CHRM1CHRM3
SCHEMBL16379315 0.82 CHRM2 (0.47) CYP1A2HIF1ACHRM2CHRM1CHRM3
SCHEMBL22000397 0.80 CHRM2 (0.49) CHRM2CHRM1CHRM3PREPEPHX1
SCHEMBL7665343 0.77 CHRM2 (0.36) CYP1A2HIF1ACHRM2CHRM1CHRM3
SCHEMBL16838718 0.76 CHRM2 (0.38) CYP1A2HIF1ACHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1118674-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE NIHON MEDIPHYSICS CO LTD (JP) 2011-01-05 EP disclosed
US-20030065183-A1 Process for producing optically active tropinonemonocarboxylic acid ester derivative NIHON MEDI-PHYSICS CO., LTD. 2003-04-03 US disclosed
US-6486323-B1 Process for producing optically active tropinonemonocarboxylic acid derivative NIHON MEDI-PHYSICS CO., LTD. (JP) 2002-11-26 US disclosed
EP-1118674-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE Nihon Medi-Physics Co., Ltd. (JP) 2001-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065183-A1 Process for producing optically active tropinonemonocarboxylic acid ester derivative CES2, FTO, HAAO CYP1A2 51/4885HIF1A 3530/4885CHRM2 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.